A Phase 3 randomized, multi-center, placebo-controlled, masked Study to evaluate the clinical efficacy and safety of Fucithalmic® (Fusidic Acid 1%) Viscous Topical Antibiotic Eye Drops for the treatment of suspected bacterial conjunctivitis.
A Phase IIb, randomized, observer-blind study to describe the safety, tolerability, and immunogenicity of MenABCWY administered on different dosing schedules in healthy adolescents.
A Phase 3a, observer-blind, randomized, controlled study to demonstrate lot-to-lot consistency and evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.
A Master Phase 1/2/3 protocol to investigate the safety, tolerability, and immunogenicity of Variant-Adapted BNT162b2 RNA-Based vaccine candidate(s) in healthy children.
A phase 2, randomized, double-blind trial to evaluate the safety, tolerability, and immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in healthy infants.
Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers.
A phase 2, randomized, double-blind, active-controlled, dose-finding clinical study to evaluate the safety, tolerability, and immunogenicity of VAX-31 in healthy infants given 4 doses at 2, 4, 6, and 12–15 months of age concomitantly with routine pediatric vaccines.